Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 15/20 | 0.52 |
| ▸ | PPARG | P37231 | 12/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901333 | 0.96 | TRPM8 (0.56) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3963601 | 0.96 | TRPM8 (0.56) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3963050 | 0.92 | PPARA (0.57) | TRPM8PPARAPPARGPPARD | |
| Tert-Butylamine SCHEMBL3962778 | 0.91 | PPARA (0.49) | TRPM8PPARAPPARGPPARD | |
| Tert-Butylamine SCHEMBL3966508 | 0.91 | PPARA (0.51) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3968760 | 0.89 | PPARA (0.56) | TRPM8PPARAPPARGPPARD | |
| Tert-Butylamine SCHEMBL3964022 | 0.89 | PPARA (0.53) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3959919 | 0.89 | PPARA (0.54) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3966524 | 0.88 | PPARA (0.59) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3963569 | 0.87 | TRPM8 (0.55) | TRPM8PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7462644-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| EP-1572626-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004056748-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | TRPM8 4238/4885PPARA 539/4885PPARG 479/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | TRPM8 4071/4885PPARA 346/4885PPARG 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.